
zzso a dual zzso inhibitor of zzso zzso 1 zzso and zzso zzso pathways zzso and zzso have synergistic zzso activity when combined in zzso zzso This phase I study aimed to determine the recommended phase II dose zzso of the combination of zzso and zzso in patients with zzso 

Patients with solid tumors who failed standard therapy or were candidates for zzso therapy were zzso zzso was administered on days 1, 8, and 15 on a zzso cycle and zzso on days 1, 4, 8, 11, 15, and zzso zzso studies were conducted during an expansion cohort of patients with advanced pancreatic zzso zzso zzso 

Forty patients were treated, 19 in the zzso phase and 21 in the expansion zzso zzso levels evaluated were zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso and zzso zzso zzso 6 + zzso One zzso toxicity zzso occurred at the highest dose level zzso zzso zzso zzso zzso zzso included zzso zzso zzso fatigue, and zzso Grade zzso zzso zzso and fatigue were seen in two, one, and two patients in the expansion zzso zzso responses were observed in zzso zzso cancer, and zzso lymphoma, including zzso zzso The zzso profile of zzso was not affected by zzso 

The zzso established in this study is zzso 1,800 zzso and zzso 1,000 zzso This regimen is well tolerated with a toxicity profile of the combination similar to the profile of zzso zzso zzso efficacy was observed in patients who previously progressed on zzso zzso 

